Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
Regeneron Pharmaceuticals (NASDAQ: REGN) unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma. The success has management planning to file for Dupixent's approval in asthma patients soon, and that suggests Dupixent could win an OK next year. If so, then this drug could end up on the fast track to becoming a billion-dollar drug.
An estimated $50 billion annually is spent directly caring for asthma patients, and a lot of that money goes toward paying for costly hospital care for patients suffering an asthma attack.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€15.60
1.640%
We see a rather positive sentiment for Teva Pharmaceutical Industries Ltd ADR with 14 Buy predictions and 1 Sell predictions.
As a result the target price of 18 € shows a slightly positive potential of 15.38% compared to the current price of 15.6 € for Teva Pharmaceutical Industries Ltd ADR.
